InvestorsHub Logo
Followers 19
Posts 1095
Boards Moderated 0
Alias Born 03/27/2013

Re: AlanC post# 269339

Wednesday, 07/31/2019 9:28:06 AM

Wednesday, July 31, 2019 9:28:06 AM

Post# of 403060
Alan,

I just wanted to remind everyone of something else that's sitting on the backburner. Yes, the dates are a bit stale, but not the concept. Which deal will come next ?? wink

"Brilacidin—Dermatology Formulation Development

Brilacidin has successfully completed Phase 2 trials in Oral Mucositis (OM), Inflammatory Bowel Disease (IBD) and Acute Bacterial Skin and Structure Infection (ABSSSI). A drug with broad platform potential (pdf), Brilacidin’s innate properties and modes of action, as well as additional pre-clinical work, support the drug’s potential for topical application in dermatology, including: Atopic Dermatitis, Acne, and Hidradenitis Suppurativa. All are areas of large unmet need and comprise highly lucrative markets.

To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.

For a discussion on Brilacidin’s potential as a topical agent in dermatology, please read more at the following link:

“Brilacidin’s Potential Application in Dermatology”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News